Summary
- Profile Type
- Business Offer
- POD Reference
- BOPL20230623009
- Term of Validity
- 23 June 2023 - 22 June 2025
- Company's Country
- Poland
- Type of partnership
- Commercial agreement
- Targeted Countries
- Sweden
- Spain
- Belgium
- Italy
- Germany
- Netherlands
- Norway
- Denmark
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
-
The company has developed a test that enables quick and minimally invasive diagnosis of endometriosis. The test is already on offer on the Polish market.
The sample can be collected using a minimally invasive method during a visit to the gynecologist, and the patient can return to her normal duties.
The company is interested in expanding their business into foreign markets and establishing cooperation with distributors in Denmark, Netherlands, Sweden, Norway, Italy, Spain, Germany and Belgium. - Full Description
-
Endometriosis is a prevalent (about 10% of the female population of childbearing age), hormonally dependent chronic disease of the female reproductive system associated with the presence of a foci of endometrial tissue (resembling the endometrium) outside the uterine cavity. The disease may be accompanied by symptoms, such as increased menstrual pain, pain during sexual intercourse, or chronic pain in the pelvic area.
The test developed by the company is an in vitro diagnostic real-time reverse transcription-PCR assay intended for quantification of the relative level of expression of the FUT4 mRNA, a marker of endometriosis in relation to the expression of GAPDH reference mRNA. Analysis is performed on RNA isolated from a biopsy taken from a patient's endometrium in the secretory phase of the menstrual cycle, in order to confirm or exclude endometriosis.
Sensitivity measures how often a test correctly generates a positive result for people with the condition being tested (also known as the “true positive” rate). The diagnostic sensitivity of the test was >94%.
Specificity measures a test’s ability to correctly generate a negative result for people who do not have the condition being tested (also known as the “true negative” rate). The diagnostic specificity of the test was >89%. - Advantages and Innovations
-
Product advantage:
• Fast diagnostic process - up to 48 hours from the moment of sample collection (depending on the laboratory occupancy) - today up to 8 years
• The PCR technique after the coronavirus epidemic is available in every city
• It is a medical device
• A quick diagnosis will allow the doctors to start treatment faster
• After taking the sample, the woman can return to her daily activities
• Other markers currently in use, such as CA 125 or Bcl6, are not specific for endometriosis - Stage of Development
- Already on the market
- Sustainable Development Goals
- Not relevant
- IPR status
- IPR granted
Partner Sought
- Expected Role of a Partner
- The company is looking for distributors and partners with experience in diagnostics business and gynaecology division. The test is dedicated for professional personal use like diagnostic laboratories or hospitals.
- Type and Size of Partner
- Big company
- SME 50 - 249
- SME 11-49
- Type of partnership
- Commercial agreement
Dissemination
- Market keywords
- 005001008 - Diagnostic test products and equipment
- Targeted countries
- Sweden
- Spain
- Belgium
- Italy
- Germany
- Netherlands
- Norway
- Denmark